Immunomodulatory Agents in Follicular Lymphoma

Publication date: Available online 8 April 2020Source: Hematology/Oncology Clinics of North AmericaAuthor(s): Loic Ysebaert, Franck Morschhauser
Source: Hematology Oncology Clinics of North America - Category: Hematology Source Type: research

Related Links:

Condition:   Relapsed / Refractory Mantle Cell Lymphoma (MCL) Intervention:   Drug: TQ-B3525 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lymphoma, Large B-Cell, Diffuse Intervention:   Biological: Nonconforming Lisocabtagene Maraleucel Sponsor:   Juno Therapeutics, a Subsidiary of Celgene Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 mont...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 months, su...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research
AbstractAngiogenesis is critical for the initiation and progression of solid tumors, as well as hematological malignancies. While angiogenesis in solid tumors has been well characterized, a large body of investigation is devoted to clarify the impact of angiogenesis on lymphoma development. B-cell non-Hodgkin lymphoma (B-NHL) is the most common lymphoid malignancy with a highly heterogeneity. The malignancy remains incurable despite that the addition of rituximab to conventional chemotherapies provides substantial improvements. Several angiogenesis-related parameters, such as proangiogenic factors, circulating endothelial ...
Source: Angiogenesis - Category: Molecular Biology Source Type: research
Diego Esteban Arias, Sara Lally, Carol ShieldsIndian Journal of Ophthalmology 2020 68(6):961-961
Source: Indian Journal of Ophthalmology - Category: Opthalmology Authors: Source Type: research
We report a case that presented as third nerve palsy but later on developed central retinal vein occlusion and was ultimately diagnosed as primary gastric lymphoma of diffuse large B cell type.
Source: Indian Journal of Ophthalmology - Category: Opthalmology Authors: Source Type: research
Condition:   Relapsed / Refractory Mantle Cell Lymphoma (MCL) Intervention:   Drug: TQ-B3525 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lymphoma, Large B-Cell, Diffuse Intervention:   Biological: Nonconforming Lisocabtagene Maraleucel Sponsor:   Juno Therapeutics, a Subsidiary of Celgene Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract BACKGROUND: Informational and supportive care resources are needed for Hodgkin lymphoma (HL) survivors. OBJECTIVES: The aim of this article is to adapt and evaluate a previously developed survivorship care website for HL survivors. METHODS: A mixed-methods, user-centered design, including one-time focus groups, was followed by iterative web design and user testing. Transcripts were content analyzed, and survey responses were summarized. FINDINGS: HL survivors need survivorship care education and support. Tailored web-based resources may be an effective adjunct to clinical care. The Survivor...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma